Press Releases

Bethesda, Maryland, May 18, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe. Fraunhofer is the largest applied research foundation in Europe, with a staff of more than 18,000 scientists, engineers, business personnel and others dedicated to practical applications and... Read More

Number Of Centers Further Expected To More Than Double This Quarter Bethesda, Maryland, May 3, 2011 — Northwest Biotherapeutics (OTC.BB:NWBO) today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company’s ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the... Read More

Bethesda, Maryland, March 16, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO). Taking note of the recent unusual activity in the Company’s stock, Northwest Biotherapeutics (NWBT) commented today that it is not aware of any basis relating to the Company or its products or programs. The Company is continuing to move forward with the trial-related activities for its large, 240-patient clinical trial for GBM brain cancer. The... Read More

Highlights Include Clinical and Corporate Updates, Striking Long-Term Data, and Lack of Toxicity, Low Cost and Simplicity of DCVax® Therapeutic Vaccines Bethesda, Maryland, February 14, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chair of the Board of Directors, Ms. Linda Powers, will give a corporate presentation at the 13th Annual Biotechnology Industry Organization’s BIO CEO &... Read More

Bethesda, MD, January 24, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax® for Glioblastoma multiforme (“GBM”) brain cancer. To date, this trial has been conducted at 13 clinical sites across the U.S., with 33 patients already having... Read More